Clinical Trial Update: Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating adjuvant immunotherapy with toripalimab after curative-intent ablation for recurrent hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Xiangya Hospital of Central South University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN